POZEN Logo
Print Page   Close Window

2006 News Releases

DateTitle 
December 13, 2006Pozen Expects to Submit Revised Response to Trexima(TM) (Sumatriptan/Naproxen Sodium) Approvable Letter by Year EndPrinter Friendly Version
December 07, 2006POZEN To Present at the 2006 RBC Capital Markets Healthcare ConferencePrinter Friendly Version
November 30, 2006POZEN to Present at the BMO 6th Annual Investor Conference - Focus on HealthcarePrinter Friendly Version
November 21, 2006POZEN to Present at the Lazard Capital Markets Third Annual Life Sciences ConferencePrinter Friendly Version
November 09, 2006POZEN Submits Full Response to FDA Approvable Letter For Trexima™Printer Friendly Version
November 01, 2006POZEN to Present at the Cowen & Company 7th Annual Global Health Care ConferencePrinter Friendly Version
October 31, 2006POZEN Reports Third Quarter 2006 ResultsPrinter Friendly Version
October 23, 2006POZEN To Ring NASDAQ Closing BellPrinter Friendly Version
October 17, 2006POZEN Announces October 31 Webcast of Third Quarter 2006 ResultsPrinter Friendly Version
September 21, 2006POZEN Announces Receipt of $40 Million Upfront Payment from AstraZeneca; Company Provides Revised 2006 GuidancePrinter Friendly Version
September 20, 2006New Analysis Shows Patients Who Treat Their Migraine Pain Early With Trexima™ (Sumatriptan Succinate/Naproxen Sodium) Have Higher Sustained Pain-Free Rates Than Those Who Treat LatePrinter Friendly Version
September 20, 2006New Data Show Consistent Efficacy and Tolerability of Trexima™ (Sumatriptan Succinate/Naproxen Sodium) Across Multiple Migraine AttacksPrinter Friendly Version
September 20, 2006New Data Show Peak Concentration of Sumatriptan Occurred Earlier With Trexima™ (Sumatriptan Succinate/Naproxen Sodium) Compared to Imitrex® (Sumatriptan Succinate)Printer Friendly Version
September 13, 2006POZEN To Present at the UBS 2006 Global Life Sciences ConferencePrinter Friendly Version
September 05, 2006POZEN To Present at the Bear Stearns 19th Annual Healthcare ConferencePrinter Friendly Version
August 03, 2006Pozen Reports Second Quarter 2006 ResultsPrinter Friendly Version
August 02, 2006POZEN and AstraZeneca Announce Global Collaboration to Co-Develop and Commercialize Fixed Dose Combinations of Naproxen and Esomeprazole for the Treatment of PainPrinter Friendly Version
July 31, 2006POZEN to Submit Full Response to Trexima™ Approvable Letter During the Fourth QuarterPrinter Friendly Version
July 25, 2006POZEN Announces August 3 Webcast of Second Quarter 2006 ResultsPrinter Friendly Version
June 26, 2006New Data Show Investigational Migraine Therapy Demonstrates Effective Treatment of Migraine-Associated Neck and Sinus PainPrinter Friendly Version
June 26, 2006New Data Demonstrate Sustained Efficacy of Single Tablet Combination Migraine Therapy Compared to MonotherapyPrinter Friendly Version
June 09, 2006POZEN Inc. and Glaxosmithkline Report Receipt of Approvable Letter for Investigational Migraine TreatmentPrinter Friendly Version
April 27, 2006POZEN Reports First Quarter 2006 ResultsPrinter Friendly Version
April 20, 2006POZEN Announces Completion of Special Protocol Assessment for PN 200; New Arthritis Product Phase III Trials to Begin on SchedulePrinter Friendly Version
April 13, 2006POZEN Announces April 27 Webcast of First Quarter 2006 ResultsPrinter Friendly Version
April 05, 2006New Data Presented on Satisfaction, Productivity and Long-Term Safety of a Single Tablet Containing Sumatriptan Formulated With RT Technology(TM) and Naproxen SodiumPrinter Friendly Version
April 05, 2006New Pivotal Trial Data Demonstrated Superior Clinical Benefits of Single Tablet Containing Sumatriptan Formulated With RT Technology(TM) and Naproxen SodiumPrinter Friendly Version
April 04, 2006POZEN to Present at the SunTrust Robinson Humphrey 35th Annual Institutional ConferencePrinter Friendly Version
March 16, 2006POZEN Announces Changes to Its Board of Directors; The Company Appoints Donald H. Namm and James J. Mauzey and Accepts the Resignations of Ted G. Wood and James R. ButlerPrinter Friendly Version
March 02, 2006POZEN to Present at Cowen & Co. 26th Annual Health Care ConferencePrinter Friendly Version
March 01, 2006POZEN Reports Fourth Quarter and Year End 2005 Results; $20 Million Milestone Payment from GSK Contributes to Profitability; Lornoxicam Phase II Studies Initiated in Acute Pain And MigrainePrinter Friendly Version
February 22, 2006POZEN Announces Change of Date for Webcast of Fourth Quarter and Year End ResultsPrinter Friendly Version
February 16, 2006POZEN Announces March 2 Webcast of Fourth Quarter and Year End ResultsPrinter Friendly Version
February 10, 2006Company Profile for POZEN Inc.Printer Friendly Version
February 09, 2006POZEN to Present on Panel at the BIO CEO & Investor ConferencePrinter Friendly Version